Page 113 - Read Online

Page 10 of 11 Kotecha et al. J Cancer Metastasis Treat 2021;7:67 https://dx.doi.org/10.20517/2394-4722.2021.163

vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol 2009;27:5794-9. DOI
PubMed
12. Motzer RJ, Bacik J, Murphy BA, Russo P, Mazumdar M. Interferon-alfa as a comparative treatment for clinical trials of new therapies
against advanced renal cell carcinoma. J Clin Oncol 2002;20:289-96. DOI PubMed
13. Choueiri TK, Halabi S, Sanford BL, et al. Cabozantinib versus sunitinib as initial targeted therapy for patients with metastatic renal
cell carcinoma of poor or intermediate risk: the alliance A031203 CABOSUN trial. J Clin Oncol 2017;35:591-7. DOI PubMed PMC
14. Hudes G, Carducci M, Tomczak P, et al; Global ARCC Trial. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma.
N Engl J Med 2007;356:2271-81. DOI PubMed
15. Motzer RJ, Banchereau R, Hamidi H, et al. Molecular subsets in renal cancer determine outcome to checkpoint and angiogenesis
blockade. Cancer Cell 2020;38:803-17.e4. DOI PubMed PMC
16. McDermott DF, Huseni MA, Atkins MB, et al. Clinical activity and molecular correlates of response to atezolizumab alone or in
combination with bevacizumab versus sunitinib in renal cell carcinoma. Nat Med 2018;24:749-57. DOI PubMed PMC
17. Hakimi AA, Voss MH, Kuo F, et al. Transcriptomic profiling of the tumor microenvironment reveals distinct subgroups of clear cell
renal cell cancer: data from a randomized phase III trial. Cancer Discov 2019;9:510-25. DOI PubMed PMC
18. Motzer R, Tannir N, Mcdermott D, et al. 661P Conditional survival and 5-year follow-up in CheckMate 214: First-line nivolumab +
ipilimumab (N+I) versus sunitinib (S) in advanced renal cell carcinoma (aRCC). Ann Oncol 2021;32:S685-7. DOI
19. Albiges L, Tannir NM, Burotto M, et al. Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell
carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial. ESMO Open 2020;5:e001079. DOI PubMed PMC
20. Tannir NM, Signoretti S, Choueiri TK, et al. Efficacy and safety of nivolumab plus ipilimumab versus sunitinib in first-line treatment
of patients with advanced sarcomatoid renal cell carcinoma. Clin Cancer Res 2021;27:78-86. DOI PubMed
21. Escudier B, Pluzanska A, Koralewski P, et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a
randomised, double-blind phase III trial. Lancet 2007;370:2103-11. DOI PubMed
22. Amin A, Plimack ER, Ernstoff MS, et al. Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or
metastatic renal cell carcinoma: the CheckMate 016 study. J Immunother Cancer 2018;6:109. DOI PubMed PMC
23. Chowdhury S, Mcdermott DF, Voss MH, et al. A phase I/II study to assess the safety and efficacy of pazopanib (PAZ) and
pembrolizumab (PEM) in patients (pts) with advanced renal cell carcinoma (aRCC). J Clin Oncol 2017;35:4506. DOI
24. Rini BI, Powles T, Atkins MB, et al. Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic
renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial. Lancet 2019;393:2404-15. DOI
PubMed
25. Powles T, Plimack ER, Soulières D, et al. Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of
advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial. Lancet Oncol
2020;21:1563-73. DOI PubMed
26. Rini BI, Plimack ER, Stus V, et al. Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for advanced clear
cell renal cell carcinoma (ccRCC): results from 42-month follow-up of KEYNOTE-426. J Clin Oncol 2021;39:4500. DOI
27. Plimack ER, Powles T, Bedke J, et al. Outcomes for patients in the pembrolizumab+axitinib arm with advanced renal cell carcinoma
(RCC) who completed two years of treatment in the phase III KEYNOTE-426 study. J Clin Oncol 2021;39:327. DOI
28. Motzer RJ, Choueiri TK, Powles T, et al. Nivolumab + cabozantinib (NIVO+CABO) versus sunitinib (SUN) for advanced renal cell
carcinoma (aRCC): Outcomes by sarcomatoid histology and updated trial results with extended follow-up of CheckMate 9ER. J Clin
Oncol 2021;39:308. DOI
29. Alhalabi O, Hasanov E, Wilson NR, et al. Outcomes of patients with intermediate-risk or poor-risk metastatic renal cell carcinoma
who received their first cycle of nivolumab and ipilimumab in the hospital because of symptomatic disease: The MD Anderson Cancer
Center experience. Int J Cancer 2021;149:387-93. DOI PubMed
30. McDermott DF, Lee JL, Bjarnason GA, et al. Open-label, single-arm phase II study of pembrolizumab monotherapy as first-line
therapy in patients with advanced clear cell renal cell carcinoma. J Clin Oncol 2021;39:1020-8. DOI PubMed PMC
31. Grimm MO, Schmidinger M, Martinez ID, et al. Tailored immunotherapy approach with nivolumab in advanced renal cell carcinoma
(TITAN-RCC). Ann Oncol 2019;30:v892. DOI
32. McKay RR, McGregor BA, Xie W, et al. Optimized management of nivolumab and ipilimumab in advanced renal cell carcinoma: a
response-based phase II study (OMNIVORE). J Clin Oncol 2020;38:4240-8. DOI PubMed PMC
33. Atkins MB, Jegede O, Haas NB, et al. Phase II study of nivolumab and salvage nivolumab + ipilimumab in treatment-naïve patients
(pts) with advanced renal cell carcinoma (RCC) (HCRN GU16-260). J Clin Oncol 2020;38:5006. DOI
34. Lee C, Shah AY, Hsieh JJ, et al. Phase II trial of lenvatinib (LEN) plus pembrolizumab (PEMBRO) for disease progression after PD-
1/PD-L1 immune checkpoint inhibitor (ICI) in metastatic clear cell renal cell carcinoma (mccRCC). J Clin Oncol 2020;38:5008. DOI
35. Epaillard N, Simonaggio A, Elaidi R, et al. BIONIKK: A phase 2 biomarker driven trial with nivolumab and ipilimumab or VEGFR
tyrosine kinase inhibitor (TKI) in naïve metastatic kidney cancer. Bulletin du Cancer 2020;107:eS22-7. DOI PubMed
36. Beuselinck B, Job S, Becht E, et al. Molecular subtypes of clear cell renal cell carcinoma are associated with sunitinib response in the
metastatic setting. Clin Cancer Res 2015;21:1329-39. DOI PubMed
37. Choueiri TK, Albiges L, Powles T, Scheffold C, Wang F, Motzer RJ. A phase III study (COSMIC-313) of cabozantinib (C) in
combination with nivolumab (N) and ipilimumab (I) in patients (pts) with previously untreated advanced renal cell carcinoma (aRCC)
of intermediate or poor risk. J Clin Oncol 2020;38:TPS767. DOI
38. Apolo AB, Nadal R, Girardi DM, et al. Phase I study of cabozantinib and nivolumab alone or with ipilimumab for advanced or
metastatic urothelial carcinoma and other genitourinary tumors. J Clin Oncol 2020;38:3672-84. DOI PubMed PMC